References
Dodick DW, Turkel CC, RE DG, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921–936
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Adams AM (2018) Long-term study of the efficacy and safety of Onabotulinumtoxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain 19:13
Headache Classification Committee of International Headache Society (2013) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 33:629–808
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Schiano di Cola, F., Pari, E., Caratozzolo, S. et al. OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort. Neurol Sci 39 (Suppl 1), 159–160 (2018). https://doi.org/10.1007/s10072-018-3391-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-018-3391-5